J
Jeffrey M. Fowler
Researcher at Ohio State University
Publications - 161
Citations - 13509
Jeffrey M. Fowler is an academic researcher from Ohio State University. The author has contributed to research in topics: Endometrial cancer & Gynecologic oncology. The author has an hindex of 48, co-authored 154 publications receiving 12116 citations. Previous affiliations of Jeffrey M. Fowler include The Ohio State University Wexner Medical Center & North Shore-LIJ Health System.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Robert F. Ozols,Brian N. Bundy,Benjamin E. Greer,Jeffrey M. Fowler,Daniel L. Clarke-Pearson,Robert A. Burger,Robert S. Mannel,Koen DeGeest,Ellen M. Hartenbach,Rebecca N. Baergen +9 more
TL;DR: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin pluspaclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus pac Litaxel.
Journal ArticleDOI
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: In this article, a double-blind, placebo-controlled, phase 3 trial was conducted to evaluate the effect of bevacizumab and paclitaxel on progression-free survival in patients with stage III or stage IV epithelial ovarian cancer.
Journal ArticleDOI
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
Maurie Markman,Brian N. Bundy,David S. Alberts,Jeffrey M. Fowler,Daniel L. Clark-Pearson,Linda F. Carson,Scott Wadler,Joshua Sickel +7 more
TL;DR: An experimental regimen including moderately high-dose IV carboplatin followed by IP paclitaxel and IV cisplatin yielded a significant improvement in progression-free survival when compared with a standard regimen of IV cis Platin and pac Litaxel.
Journal ArticleDOI
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: This multinational double-blind placebo-controlled trial was designed to evaluate the addition of bevacizumab to standard front-line ovarian cancer therapy in patients with stage III or IV epithelial ovarian cancer.
Journal ArticleDOI
Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
Marcus E. Randall,Virginia L. Filiaci,Hyman B. Muss,Nick M. Spirtos,Robert S. Mannel,Jeffrey M. Fowler,J. Tate Thigpen,Jo Ann Benda +7 more
TL;DR: Chemotherapy with AP significantly improved progression-free and overall survival compared with WAI, and further advances in efficacy and reduction in toxicity are clearly needed.